A Study to Evaluate Alzheimer Disease Biomarkers in Cerebrospinal Fluid (CSF)

Overview

About this study

The purpose of this study is to validate the Alzheimer Disease Biomarkers assays (Phospho-Tau/Total-Tau/Ab42) being implemented at Mayo to compare them to the referral tests in support of test validation efforts.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients undergoing a spinal tab for CSF collection and in whom the referral test ADmark Phospho-Tau/Total-Tau/Ab42 has been ordered.

Exclusion Criteria: 

  • All subjects not meeting inclusion criteria

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Alicia Algeciras-Schimnich, Ph.D.

Open for enrollment

Contact information:

Mohamed Ibrahim

(507)284-4115

Ibrahim.Mohamed@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20462565

Mayo Clinic Footer